GENPF: AI 评分 38/100 — AI 分析 (4月 2026)

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products, focusing on nutraceuticals and pharmaceuticals in Canada. The company develops and sells a range of products, including antiviral treatments, dietary supplements, and nutraceuticals.

Key Facts: AI Score: 38/100 Sector: Healthcare

公司概况

概要：

Genix Pharmaceuticals Corporation is a Canadian life sciences company focused on developing, manufacturing, and marketing nutraceuticals and pharmaceuticals. Their product portfolio includes antiviral treatments like Flu-X, dietary supplements such as Renochlor, and a variety of nutraceutical products, positioning them in the specialty and generic drug market.

GENPF是做什么的？

Genix Pharmaceuticals Corporation, formerly known as Alta Natural Herbs & Supplements Ltd., was incorporated in 1993 and rebranded in June 2019 to reflect its expanded focus on pharmaceuticals. Based in Vancouver, Canada, the company formulates, manufactures, licenses, and markets life sciences related products. Genix Pharmaceuticals operates primarily in the nutraceutical and pharmaceutical sectors, developing products aimed at addressing various health needs. Their key products include Flu-X, an herbal antiviral product targeting flu and common cold coronaviruses, available in oral and spray forms; Renochlor, a dietary supplement designed to support kidney health and function; and Sucanon, an insulin sensitizer intended to lower blood sugar levels. Additionally, Genix Pharmaceuticals markets a range of nutraceuticals, including bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, lecithin softgels, fish oil softgels, EPO softgels, and spirulina powder. The company also offers eye ointments and drops, further diversifying its product offerings within the healthcare market. Genix Pharmaceuticals aims to provide accessible and effective healthcare solutions through its diverse product line.

GENPF的投资论点是什么？

Genix Pharmaceuticals Corporation presents a speculative investment opportunity within the specialty and generic drug market. The company's focus on nutraceuticals and pharmaceuticals, including novel products like Flu-X and Renochlor, could drive revenue growth if these products gain market acceptance. However, the company's small market capitalization and OTC listing introduce significant risks. Key value drivers include successful product commercialization, expansion of distribution networks, and potential partnerships. The negative P/E ratio of -3.80 indicates the company is currently not profitable, requiring careful monitoring of financial performance. The beta of 0.49 suggests lower volatility compared to the overall market. Investors should assess the company's ability to execute its growth strategy and navigate the competitive landscape.

GENPF在哪个行业运营？

Genix Pharmaceuticals Corporation operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and evolving regulatory landscapes. The global nutraceuticals market is experiencing steady growth, driven by increasing consumer awareness of preventive healthcare and the rising prevalence of chronic diseases. The pharmaceutical industry is also undergoing significant changes, with a growing emphasis on generic drugs and biosimilars to reduce healthcare costs. Genix Pharmaceuticals competes with both established pharmaceutical companies and smaller nutraceutical manufacturers. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products.

Drug Manufacturers - Specialty & Generic

Healthcare

GENPF有哪些增长机遇？

Expansion of Product Portfolio: Genix Pharmaceuticals can expand its product portfolio by developing and launching new nutraceutical and pharmaceutical products. The global nutraceuticals market is projected to reach $500 billion by 2025, providing ample opportunities for growth. Timeline: Ongoing.
Geographic Expansion: Genix Pharmaceuticals can expand its geographic reach beyond Canada by entering new markets in North America, Europe, and Asia. The increasing demand for nutraceuticals and generic drugs in these regions presents significant growth opportunities. Timeline: 2-3 years.
Strategic Partnerships: Genix Pharmaceuticals can form strategic partnerships with distributors, retailers, and other healthcare providers to expand its distribution network and reach a wider customer base. Collaborations can also facilitate product development and marketing efforts. Timeline: Ongoing.
Online Sales and Marketing: Genix Pharmaceuticals can invest in online sales and marketing channels to reach a broader audience and increase brand awareness. E-commerce platforms and digital marketing campaigns can drive sales and reduce reliance on traditional distribution channels. Timeline: 1 year.
Research and Development: Genix Pharmaceuticals can invest in research and development to develop innovative products and gain a competitive edge. Focusing on novel formulations and delivery systems can differentiate the company from its competitors. Timeline: Ongoing.

Focus on nutraceuticals and pharmaceuticals, targeting a growing market segment.
Development of Flu-X, an antiviral product, addressing the demand for cold and flu remedies.
Renochlor, a dietary supplement, caters to the increasing awareness of kidney health.
Sucanon, an insulin sensitizer, aims to address the needs of individuals managing blood sugar levels.
OTC listing provides access to capital but also introduces higher risks and regulatory scrutiny.

GENPF提供哪些产品和服务？

Formulates and manufactures nutraceuticals and pharmaceuticals.
Licenses and markets life sciences related products.
Develops antiviral products like Flu-X.
Offers dietary supplements such as Renochlor.
Markets insulin sensitizers like Sucanon.
Sells a range of nutraceutical products, including bee propolis capsules and fish oil softgels.
Provides eye ointments and drops.

GENPF如何赚钱？

Develops and manufactures nutraceutical and pharmaceutical products.
Markets and sells products through various distribution channels.
Generates revenue through product sales and licensing agreements.

Individuals seeking nutraceuticals and dietary supplements.
Patients requiring pharmaceutical treatments.
Retailers and distributors of healthcare products.

Proprietary formulations for certain products.
Established manufacturing capabilities.
Brand recognition in the Canadian market.

什么因素可能推动GENPF股价上涨？

Upcoming: Potential regulatory approvals for new pharmaceutical products.
Ongoing: Expansion of distribution networks and strategic partnerships.
Ongoing: Increasing demand for nutraceuticals and dietary supplements.
Upcoming: Positive clinical trial results for key products.
Ongoing: Growth in online sales and marketing efforts.

GENPF的主要风险是什么？

Potential: Intense competition from established pharmaceutical companies.
Potential: Evolving regulatory landscape and compliance requirements.
Ongoing: Limited financial resources and profitability.
Potential: Product liability claims and recalls.
Ongoing: Economic downturn affecting consumer spending.

GENPF的核心优势是什么？

Diverse product portfolio in nutraceuticals and pharmaceuticals.
Development of innovative products like Flu-X and Renochlor.
Established manufacturing capabilities.
Presence in the Canadian market.

GENPF的劣势是什么？

Small market capitalization.
OTC listing increases risk and regulatory scrutiny.
Negative P/E ratio indicates lack of profitability.
Limited geographic reach.

GENPF有哪些机遇？

Expansion into new geographic markets.
Strategic partnerships with distributors and retailers.
Development of new and innovative products.
Increased online sales and marketing efforts.

GENPF面临哪些威胁？

Intense competition from established pharmaceutical companies.
Evolving regulatory landscape.
Potential product liability claims.
Economic downturn affecting consumer spending.

GENPF的竞争对手是谁？

BioSpark Technologies Corp. — Focuses on biotechnology and pharmaceutical research. — (BSPK)
Cryomass Technologies Inc. — Specializes in cryogenic technologies for various applications. — (CRYM)
Cannavaro Greenly PLC — Operates in the cannabis and hemp industry. — (CVGRF)
IGEX Investments, Inc. — Investment company with holdings in various sectors. — (IGEX)
Kaysun Corporation — Develops and markets consumer products. — (KAYS)

Key Metrics

MoonshotScore: 38/100

Company Profile

CEO: Sina Salehi Pirooz
Headquarters: Vancouver, CA
Founded: 2020

AI Insight

AI analysis pending for GENPF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Genix Pharmaceuticals Corporation do?

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company develops and sells products like Flu-X, an antiviral treatment; Renochlor, a dietary supplement for kidney health; and Sucanon, an insulin sensitizer. Additionally, they offer a range of nutraceuticals, including vitamins, supplements, and eye care products. Genix aims to provide accessible healthcare solutions through its diverse product line, targeting both the pharmaceutical and nutraceutical markets.

What do analysts say about GENPF stock?

As of March 15, 2026, formal analyst coverage of Genix Pharmaceuticals Corporation (GENPF) appears limited, likely due to its OTC market listing and smaller market capitalization. Key valuation metrics, such as the negative P/E ratio, reflect the company's current lack of profitability. Growth considerations center on the successful commercialization of its key products and expansion into new markets. Investors should conduct thorough due diligence and assess the company's financial performance and growth prospects independently.

What are the main risks for GENPF?

Genix Pharmaceuticals Corporation faces several key risks. Intense competition from larger, established pharmaceutical companies poses a significant challenge. The evolving regulatory landscape for pharmaceuticals and nutraceuticals could impact the company's ability to market and sell its products. Limited financial resources and lack of profitability create financial sustainability concerns. Product liability claims and recalls represent additional risks. Furthermore, as an OTC-listed company, GENPF faces increased scrutiny and potential liquidity issues.